Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 1/2016

Open Access 01-12-2016 | Review

The role of cytokines in the pathogenesis and staging of Trypanosoma brucei rhodesiense sleeping sickness

Authors: Charles D. Kato, Enock Matovu, Claire. M. Mugasa, Ann Nanteza, Vincent P. Alibu

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2016

Login to get access

Abstract

Human African trypanosomiasis due to Trypanosoma brucei rhodesiense is invariably fatal if untreated with up to 12.3 million people at a risk of developing the disease in Sub-Saharan Africa. The disease is characterized by a wide spectrum of clinical presentation coupled with differences in disease progression and severity. While the factors determining this varied response have not been clearly characterized, inflammatory cytokines have been partially implicated as key players. In this review, we consolidate available literature on the role of specific cytokines in the pathogenesis of T. b. rhodesiense sleeping sickness and further discuss their potential as stage biomarkers. Such information would guide upcoming research on the immunology of sleeping sickness and further assist in the selection and evaluation of cytokines as disease stage or diagnostic biomarkers.
Literature
1.
Welburn SC, Fèvre EM, Coleman PG, Odiit M, Maudlin I. Sleeping sickness: a tale of two diseases. Trends Parasitol. 2001;17(1):19–24.PubMedCrossRef
2.
Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, et al. The trypanosomiases. Lancet. 2003;362(9394):1469–80.PubMedCrossRef
3.
Foulkes J. The six diseases WHO. Human trypanosomiasis in Africa. Br Med J. 1981;283(6300):1172–4.CrossRef
4.
5.
Matemba LE, Fèvre EM, Kibona SN, Picozzi K, Cleaveland S, Shaw AP, et al. Quantifying the burden of rhodesiense sleeping sickness in Urambo District, Tanzania. PLoS Negl Trop Dis. 2010;4(11):e868.PubMedCentralPubMedCrossRef
6.
Odiit M, Coleman P, Liu WC, McDermott J, Fevre E, Welburn S, et al. Quantifying the level of under-detection of Trypanosoma brucei rhodesiense sleeping sickness cases. Trop Med Int Health. 2005;10(9):840–9.PubMedCrossRef
7.
Kato CD, Nanteza A, Mugasa C, Edyelu A, Matovu E, Alibu VP. Clinical profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients in Uganda. PLoS One. 2015;10(2):e0118370.PubMedCentralPubMedCrossRef
8.
MacLean LM, Chisi JE, Odiit M, Gibson WC, Ferris V, Picozzi K, et al. Severity of human African trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun. 2004;72(12):7040–4.PubMedCentralPubMedCrossRef
9.
MacLean LM, Odiit M, Chisi JE, Kennedy PG, Sternberg JM. Focus-specific clinical profiles in human African trypanosomiasis caused by Trypanosoma brucei rhodesiense. PLoS Negl Trop Dis. 2010;4(12):e906.PubMedCentralPubMedCrossRef
10.
Ormerod W. Taxonomy of the sleeping sickness trypanosomes. The Journal of parasitology. 1967:824-30.
11.
Blum J, Neumayr A, Hatz C. Human African trypanosomiasis in endemic populations and travellers. Eur J Clin Microbiol Infect Dis. 2012;31(6):905–13.PubMedCrossRef
12.
Duggan AJ, Hutchinson MP. Sleeping sickness in Europeans: a review of 109 cases. J Trop Med Hyg. 1966;69(6):124–31.PubMed
13.
MacLean LM, Odiit M, MacLeod A, Morrison L, Sweeney L, Cooper A, et al. Spatially and genetically distinct African Trypanosome virulence variants defined by host interferon-γ response. J Infect Dis. 2007;196(11):1620–8.PubMedCentralPubMedCrossRef
14.
Sternberg JM, MacLean L. A spectrum of disease in human African trypanosomiasis: the host and parasite genetics of virulence. Parasitology. 2010;137(14):2007–15.PubMedCrossRef
15.
Sternberg JM, Rodgers J, Bradley B, MacLean L, Murray M, Kennedy PG. Meningoencephalitic African trypanosomiasis: brain IL-10 and IL-6 are associated with protection from neuro-inflammatory pathology. J Neuroimmunol. 2005;167(1):81–9.PubMedCrossRef
16.
Kennedy PG. Cytokines in central nervous system trypanosomiasis: cause, effect or both? Trans R Soc Trop Med Hyg. 2009;103(3):213–4.PubMedCrossRef
17.
18.
Hertz CJ, Filutowicz H, Mansfield JM. Resistance to the African trypanosomes is IFN-gamma dependent. J immunol (Baltimore, Md: 1950). 1998;161(12):6775–83.
19.
20.
Kuepfer I, Hhary EP, Allan M, Edielu A, Burri C, Blum JA. Clinical presentation of Tb rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl Trop Dis. 2011;5(3):e968.PubMedCentralPubMedCrossRef
21.
22.
23.
WHO. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1998;881:1–114 (I-VI).
24.
Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375(9709):148–59.PubMedCrossRef
25.
Miezan TW, Meda AH, Doua F, Cattand P. Evaluation of the parasitologic technics used in the diagnosis of human Trypanosoma gambiense trypanosomiasis in the Ivory Coast. Bull soc Pathol Exot (1990). 1994;87(2):101–4.
26.
Ancelle T, Paugam A, Bourlioux F, Merad A, Vigier JP. Detection of trypanosomes in blood by the Quantitative Buffy Coat (QBC) technique: experimental evaluation. Med Trop (Mars). 1997;57(3):245–8.
27.
Truc P, Jamonneau V, N’Guessan P, Diallo P, Garcia A. Parasitological diagnosis of human African trypanosomiasis: a comparison of the QBC® and miniature anion-exchange centrifugation techniques. Trans R Soc Trop Med Hyg. 1998;92(3):288–9.PubMedCrossRef
28.
Woo PT. The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. Acta Trop. 1970;27(4):384–6.PubMed
29.
Woo PT. Evaluation of the haematocrit centrifuge and other techniques for the field diagnosis of human trypanosomiasis and filariasis. Acta Trop. 1971;28(3):298–303.PubMed
30.
Lumsden W, Kimber C, Evans D, Doig S. Trypanosoma brucei: miniature anion-exchange centrifugation technique for detection of low parasitaemias: adaptation for field use. Trans R Soc Trop Med Hyg. 1979;73(3):312–7.PubMedCrossRef
31.
Camara M, Camara O, Ilboudo H, Sakande H, Kaboré J, N’Dri L, et al. Sleeping sickness diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange centrifugation test. Trop Med Int Health. 2010;15(7):796–9.PubMedCrossRef
32.
Van Xong H, Vanhamme L, Chamekh M, Chimfwembe CE, Van Den Abbeele J, Pays A, et al. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell. 1998;95(6):839–46.PubMedCrossRef
33.
De Greef C, Imberechts H, Matthyssens G, Van Meirvenne N, Hamers R. A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol. 1989;36(2):169–76.PubMedCrossRef
34.
Radwanska M, Chamekh M, Vanhamme L, Claes F, Magez S, Magnus E, et al. The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. Am J Trop Med Hyg. 2002;67(6):684–90.PubMed
35.
Jamonneau V, Solano P, Garcia A, Lejon V, Dje N, Miezan T, et al. Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Cote d’Ivoire. Trop Med Int Health. 2003;8(7):589–94.PubMedCrossRef
36.
Kuboki N, Inoue N, Sakurai T, Di Cello F, Grab DJ, Suzuki H, et al. Loop-mediated isothermal amplification for detection of African trypanosomes. J Clin Microbiol. 2003;41(12):5517–24.PubMedCentralPubMedCrossRef
37.
Njiru ZK, Mikosza ASJ, Armstrong T, Enyaru JC, Ndung’u JM, Thompson ARC. Loop-mediated isothermal amplification (LAMP) method for rapid detection of Trypanosoma brucei rhodesiense. PLoS Negl Trop Dis. 2008;2(2):e147.PubMedCentralPubMedCrossRef
38.
Mugasa CM, Laurent T, Schoone GJ, Kager PA, Lubega GW, Schallig HD. Nucleic acid sequence-based amplification with oligochromatography for detection of Trypanosoma brucei in clinical samples. J Clin Microbiol. 2009;47(3):630–5.PubMedCentralPubMedCrossRef
39.
Deborggraeve S, Claes F, Laurent T, Mertens P, Leclipteux T, Dujardin J, et al. Molecular dipstick test for diagnosis of sleeping sickness. J Clin Microbiol. 2006;44(8):2884–9.PubMedCentralPubMedCrossRef
40.
Amin DN, Ngoyi DM, Nhkwachi G-M, Palomba M, Rottenberg M, Büscher P, et al. Identification of stage biomarkers for human African trypanosomiasis. Am J Trop Med Hyg. 2010;82(6):983–90.PubMedCentralPubMedCrossRef
41.
Hainard A, Tiberti N, Robin X, Lejon V, Ngoyi DM, Matovu E, et al. A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. PLoS Negl Trop Dis. 2009;3(6):e459.PubMedCentralPubMedCrossRef
42.
Molina-Portela MP, Samanovic M, Raper J. Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. J Exp Med. 2008;205(8):1721–8.PubMedCentralPubMedCrossRef
43.
Vanhollebeke B, Truc P, Poelvoorde P, Pays A, Joshi PP, Katti R, et al. Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. N Engl J Med. 2006;355(26):2752–6.PubMedCrossRef
44.
Vanhollebeke B, Nielsen MJ, Watanabe Y, Truc P, Vanhamme L, Nakajima K, et al. Distinct roles of haptoglobin-related protein and apolipoprotein L-I in trypanolysis by human serum. Proc Natl Acad Sci USA. 2007;104(10):4118–23.PubMedCentralPubMedCrossRef
45.
Pays E. The variant surface glycoprotein as a tool for adaptation in African trypanosomes. Microbes Infect. 2006;8(3):930–7.PubMedCrossRef
46.
Ferrante A, Allison A. Alternative pathway activation of complement by African trypanosomes lacking a glycoprotein coat. Parasite Immunol. 1983;5(5):491–8.PubMedCrossRef
47.
Black S, Hewett RS. Trypanosoma brucei variable surface antigen is released by degenerating parasites but not by actively dividing parasites. Parasite Immunol. 1982;4(4):233–44.PubMedCrossRef
48.
Dubois ME, Demick KP, Mansfield JM. Trypanosomes expressing a mosaic variant surface glycoprotein coat escape early detection by the immune system. Infect Immun. 2005;73(5):2690–7.PubMedCentralPubMedCrossRef
49.
Magez S, Stijlemans B, Baral T, De Baetselier P. VSG-GPI anchors of African trypanosomes: their role in macrophage activation and induction of infection-associated immunopathology. Microbes Infect. 2002;4(9):999–1006.PubMedCrossRef
50.
51.
Pentreath V. Trypanosomiasis and the nervous system: pathology and immunology. Trans R Soc Trop Med Hyg. 1995;89(1):9–15.PubMedCrossRef
52.
Lejon V, Büscher P, Magnus E, Moons A, Wouters I, Van Meirvenne N. A semi-quantitative ELISA for detection of Trypanosoma brucei gambiense specific antibodies in serum and cerebrospinal fluid of sleeping sickness patients. Acta Trop. 1998;69(2):151–64.PubMedCrossRef
53.
Magez S, Schwegmann A, Atkinson R, Claes F, Drennan M, De Baetselier P, et al. The role of B-cells and IgM antibodies in parasitemia, anemia, and VSG switching in Trypanosoma brucei-infected mice. PLoS Pathog. 2008;4(8):e1000122.PubMedCentralPubMedCrossRef
54.
Reinitz DM, Mansfield JM. T-cell-independent and T-cell-dependent B-cell responses to exposed variant surface glycoprotein epitopes in trypanosome-infected mice. Infect Immun. 1990;58(7):2337–42.PubMedCentralPubMed
55.
Stijlemans B, Guilliams M, Raes G, Beschin A, Magez S, De Baetselier P. African trypanosomosis: from immune escape and immunopathology to immune intervention. Vet Parasitol. 2007;148(1):3–13.PubMedCrossRef
56.
Ngotho M, Kagira J, Jensen H, Karanja S, Farah I, Hau J. Immunospecific immunoglobulins and IL-10 as markers for Trypanosoma brucei rhodesiense late stage disease in experimentally infected vervet monkeys. Trop Med Int Health. 2009;14(7):736–47.PubMedCrossRef
57.
Hertz CJ, Mansfield JM. IFN-γ-dependent nitric oxide production is not linked to resistance in experimental African trypanosomiasis. Cell Immunol. 1999;192(1):24–32.PubMedCrossRef
58.
Hunter CA, Jennings FW, Kennedy PG, Murray M. Astrocyte activation correlates with cytokine production in central nervous system of Trypanosoma brucei brucei-infected mice. Lab Invest. 1992;67(5):635–42.PubMed
59.
Kaushik RS, Uzonna JE, Zhang Y, Gordon JR, Tabel H. Innate resistance to experimental African trypanosomiasis: differences in cytokine (TNF-α, IL-6, IL-10 and IL-12) production by bone marrow-derived macrophages from resistant and susceptible mice. Cytokine. 2000;12(7):1024–34.PubMedCrossRef
60.
Maina N, Ngotho JM, Were T, Thuita JK, Mwangangi DM, Kagira JM, et al. Proinflammatory cytokine expression in the early phase of Trypanosoma brucei rhodesiense infection in vervet monkeys (Cercopithecus aethiops). Infect Immun. 2004;72(5):3063–5.PubMedCentralPubMedCrossRef
61.
Namangala B, Noël W, De Baetselier P, Brys L, Beschin A. Relative contribution of interferon-γ and interleukin-10 to resistance to murine African trypanosomosis. J Infect Dis. 2001;183(12):1794–800.PubMedCrossRef
62.
Namangala B, De Baetselier P, Beschin A. Both type-I and type-II responses contribute to murine trypanotolerance. J Vet Med Sci. 2009;71(3):313–8.PubMedCrossRef
63.
Bucheton B, MacLeod A, Jamonneau V. Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections. Parasite Immunol. 2011;33(8):438–47.PubMedCentralPubMedCrossRef
64.
Rhind SG, Sabiston BH, Shek PN, Buguet A, Muanga G, Stanghellini A, et al. Effect of melarsoprol treatment on circulating IL-10 and TNF-α levels in human African trypanosomiasis. Clin Immunol Immunopathol. 1997;83(2):185–9.PubMedCrossRef
65.
Magez S, Stijlemans B, Radwanska M, Pays E, Ferguson MA, De Baetselier P. The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. J Immunol (Baltimore, Md: 1950). 1998;160(4):1949–56.
66.
Magez S, Geuskens M, Beschin A, Del Favero H, Verschueren H, Lucas R, et al. Specific uptake of tumor necrosis factor-α is involved in growth control of Trypanosoma brucei. J Cell Biol. 1997;137(3):715–27.PubMedCentralPubMedCrossRef
67.
Magez S, Radwanska M, Beschin A, Sekikawa K, De Baetselier P. Tumor necrosis factor alpha is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect Immun. 1999;67(6):3128–32.PubMedCentralPubMed
68.
Naessens J, Kitani H, Nakamura Y, Yagi Y, Sekikawa K, Iraqi F. TNF-a mediates the development of anaemia in a murine Trypanosoma brucei rhodesiense infection, but not the anaemia associated with a murine Trypanosoma congolense infection. Clin Exp Immunol. 2005;139(3):405–10.PubMedCentralPubMedCrossRef
69.
Dauloue`d S, Bouteille B, Moynet D, Lemesre J, Buguet A, Cespuglio R, et al. Human macrophage tumor necrosis factor (TNF)-a production induced by Trypanosoma brucei gambiense and the Role of TNF-a in parasite control. J Infect Dis. 2001;183:988–91.CrossRef
70.
Amin DN, Vodnala SK, Masocha W, Sun B, Kristensson K, Rottenberg ME. Distinct toll-like receptor signals regulate cerebral parasite load and interferon α/β and tumor necrosis factor α–dependent t-cell infiltration in the brains of Trypanosoma brucei—Infected Mice. J Infect Dis. 2012;205(2):320–32. doi:10.​1093/​infdis/​jir734.PubMedCentralPubMedCrossRef
71.
MacLean LM, Odiit M, Sternberg JM. Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis. 2001;184(8):1086–90.PubMedCrossRef
72.
Lejon V, Lardon J, Kenis G, Pinoges L, Legros D, Bisser S, et al. Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment. Trans R Soc Trop Med Hyg. 2002;96(3):329–33.PubMedCrossRef
73.
Mabbott N, Coulson P, Smythies L, Wilson R, Sternberg J. African trypanosome infections in mice that lack the interferon-gamma receptor gene: nitric oxide-dependent and-independent suppression of T-cell proliferative responses and the development of anaemia. Immunology. 1998;94(4):476.PubMedCentralPubMedCrossRef
74.
Olsson T, Bakhiet M, Edlund C, Höjeberg B, van der Meide PH, Kristensson K. Bidirectional activating signals between Trypanosoma brucei and CD8 + T cells: A trypanosome-released factor triggers interferon-γ production that stimulates parasite growth. Eur J Immunol. 1991;21(10):2447–54.PubMedCrossRef
75.
Masocha W, Robertson B, Rottenberg ME, Mhlanga J, Sorokin L, Kristensson K. Cerebral vessel laminins and IFN-γ define Trypanosoma brucei brucei penetration of the blood-brain barrier. J Clin Invest. 2004;114(5):689.PubMedCentralPubMedCrossRef
76.
77.
Pizarro TT, Cominelli F. Cloning IL-1 and the birth of a new era in cytokine biology. J Immunol. 2007;178(9):5411–2.PubMedCrossRef
78.
Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990;75(1):40–7.PubMed
79.
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–50.PubMedCrossRef
80.
Ludigs K, Parfenov V, Du Pasquier RA, Guarda G. Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cell Mol Life Sci. 2012;69(20):3395–418.PubMedCrossRef
81.
Argaw AT, Zhang Y, Snyder BJ, Zhao ML, Kopp N, Lee SC, et al. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol (Baltimore, Md: 1950). 2006;177(8):5574–84.CrossRef
82.
Quan N, He L, Lai W. Intraventricular infusion of antagonists of IL-1 and TNFα attenuates neurodegeneration induced by the infection of Trypanosoma brucei. J Neuroimmunol. 2003;138(1):92–8.PubMedCrossRef
83.
Quan N, Mhlanga JD, Whiteside MB, McCoy AN, Kristensson K, Herkenham M. Chronic overexpression of proinflammatory cytokines and histopathology in the brains of rats infected with Trypanosoma brucei. J Comp Neurol. 1999;414(1):114–30.PubMedCrossRef
84.
Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-β. Immunol Today. 1989;10(8):258–61.PubMedCrossRef
85.
Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J Exp Med. 1987;166(2):571–6.PubMedCrossRef
86.
87.
Kushima Y, Hatanaka H. Interleukin-6 and leukemia inhibitory factor promote the survival of acetylcholinesterase-positive neurons in culture from embryonic rat spinal cord. Neurosci Lett. 1992;143(1):110–4.PubMedCrossRef
88.
Oka T, Oka K, Hosoi M, Hori T. Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res. 1995;692(1):123–8.PubMedCrossRef
89.
90.
Brett FM, Mizisin AP, Powell HC, Campbell IL. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing lnterleukin-6 in astrocytes. J Neuropathol Exp Neurol. 1995;54(6):766–75.PubMedCrossRef
91.
92.
MacLean LM, Odiit M, Sternberg JM. Intrathecal cytokine responses in Trypanosoma brucei rhodesiense sleeping sickness patients. Trans R Soc Trop Med Hyg. 2006;100(3):270–5.PubMedCrossRef
93.
Courtin D, Jamonneau V, Mathieu JF, Koffi M, Milet J, Yeminanga CS, et al. Comparison of cytokine plasma levels in human African trypanosomiasis. Trop Med Int Health. 2006;11(5):647–53.PubMedCrossRef
94.
95.
Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu D-H, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA. 1992;89(5):1890–3.PubMedCentralPubMedCrossRef
96.
Hunt NH, Grau GE. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol. 2003;24(9):491–9.PubMedCrossRef
97.
Sarciron M, Gherardi A. Cytokines involved in Toxoplasmic encephalitis. Scand J Immunol. 2000;52(6):534–43.PubMedCrossRef
98.
Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.CrossRef
99.
Kennedy PG. Difficulties in diagnostic staging of human African trypanosomiasis. J Neuroparasitol. 2011;2:1–3.CrossRef
100.
101.
Lejon V, Roger I, Ngoyi DM, Menten J, Robays J, N’Siesi FX, et al. Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis. Clin Infect Dis. 2008;47(1):15–22.PubMedCrossRef
102.
103.
Courtioux B, Pervieux L, Vatunga G, Marin B, Josenando T, Jauberteau-Marchan MO, et al. Increased CXCL-13 levels in human African trypanosomiasis meningo-encephalitis. Trop Med Int Health. 2009;14(5):529–34.PubMedCrossRef
104.
Hainard A, Tiberti N, Robin X, Ngoyi DM, Matovu E, Enyaru JC, et al. Matrix metalloproteinase-9 and intercellular adhesion molecule 1 are powerful staging markers for human African trypanosomiasis. Trop Med Int Health. 2011;16(1):119–26.PubMedCrossRef
105.
Tiberti N, Hainard A, Lejon V, Courtioux B, Matovu E, Enyaru JC, et al. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS One. 2012;7(7):e40909.PubMedCentralPubMedCrossRef
106.
Tiberti N, Hainard A, Lejon V, Robin X, Ngoyi DM, Turck N, et al. Discovery and verification of osteopontin and β-2-microglobulin as promising markers for staging human African trypanosomiasis. Mol Cell Proteomics. 2010;9(12):2783–95.PubMedCentralPubMedCrossRef
107.
108.
da Costa AG, Antonelli LR, Costa PA, Pimentel JP, Garcia NP, Tarrago AM, et al. The robust and modulated biomarker network elicited by the Plasmodium vivax infection is mainly mediated by the IL-6/IL-10 axis and is associated with the parasite load. J Immunol Res. 2014;2014:318250. doi:10.​1155/​2014/​318250.PubMedCrossRef
109.
Lucas R, Magez S, Songa B, Darji A, Hamers R, De Baetselier P. A role for TNF during African trypanosomiasis: involvement in parasite control immunosuppression and pathology. Res Immunol. 1993;144(5):370–6.PubMedCrossRef
Metadata
Title
The role of cytokines in the pathogenesis and staging of Trypanosoma brucei rhodesiense sleeping sickness
Authors
Charles D. Kato
Enock Matovu
Claire. M. Mugasa
Ann Nanteza
Vincent P. Alibu
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Allergy, Asthma & Clinical Immunology / Issue 1/2016
Electronic ISSN: 1710-1492
DOI
https://doi.org/10.1186/s13223-016-0113-5

Other articles of this Issue 1/2016

Allergy, Asthma & Clinical Immunology 1/2016 Go to the issue

Case report

Post-vaccination myositis and myocarditis in a previously healthy male

Research

Antibiotic prescription and food allergy in young children

Review

Potential factors involved in the causation of rhabdomyolysis following status asthmaticus

Research

Allergen inhalation challenge, refractoriness and the effects of ibuprofen

Research

Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10-year experience in Auckland, New Zealand

Short report

Asthma in the elderly: the effect of choline supplementation